Theriva Biologics Profit Margin

The latest profit margin for TOVX is -3412.67% as of September 2026. That compares with -17006.49% in the prior-year period — up 79.9% year over year. That is below the Healthcare sector average of 19.13%. Investors often review this figure alongside Theriva Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TOVX's profit margin moved from -17006.49% to -3412.67% — a 79.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Theriva Biologics's valuation or profitability profile.

Against Healthcare companies, TOVX currently prints -3412.67% for profit margin, while the sector average sits near 19.13%. That is roughly 17938.1% below the sector mean. Large gaps often invite a closer look at Theriva Biologics's growth, margins, and balance sheet.

Profit Margin shows how effectively Theriva Biologics converts resources into returns. At -3412.67%, TOVX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -17006.49% in the prior-year period — up 79.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TOVX's profit margin (-3412.67%), review year-over-year change from -17006.49%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.